Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine

Graefes Arch Clin Exp Ophthalmol. 2000 Feb;238(2):149-52. doi: 10.1007/pl00007883.

Abstract

Purpose: The aim of this study was to determine allergic responses to clonidine hydrochloride 0.25% in glaucoma patients with proven allergic reaction to apraclonidine 0.5%.

Methods: Fifteen consecutive glaucoma patients with allergic reaction to apraclonidine were prospectively challenged with clonidine hydrochloride 0.25% and evaluated for recurrence of allergic reactions and efficacy of treatment. Intraocular pressure (IOP), conjunctival hyperemia, blood pressure and resting pulse rate were determined at baseline and after 1, 3, 6 and 12 months.

Results: None of the patients developed ocular allergic reaction during 12 months on clonidine therapy. Blood pressure and pulse rate did not change significantly with clonidine treatment. Clonidine caused a significant reduction of IOP from baseline. In one patient, topical clonidine caused fatigue, dizziness and dry mouth.

Conclusion: Clonidine did not cause allergic reaction in patients with proven allergy to apraclonidine, indicating that there is no cross-reactivity with apraclonidine. Due to the small series, however, we cannot assume that allergy will not occur with clonidine 0.25% given time and a larger number of patients.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adrenergic alpha-Agonists* / administration & dosage
  • Adrenergic alpha-Agonists* / adverse effects
  • Adult
  • Aged
  • Aged, 80 and over
  • Clonidine / administration & dosage
  • Clonidine / adverse effects
  • Clonidine / analogs & derivatives*
  • Clonidine / therapeutic use*
  • Conjunctivitis, Allergic / chemically induced
  • Drug Hypersensitivity / etiology*
  • Exfoliation Syndrome / drug therapy*
  • Female
  • Glaucoma, Open-Angle / drug therapy*
  • Humans
  • Intraocular Pressure / drug effects
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Treatment Outcome

Substances

  • Adrenergic alpha-Agonists
  • Ophthalmic Solutions
  • apraclonidine
  • Clonidine